Wedbush Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $29
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Laura Chico has maintained a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) and lowered the price target from $32 to $29.
August 07, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Apellis Pharmaceuticals' price target has been lowered from $32 to $29 by Wedbush, while maintaining a Neutral rating.
The lowering of the price target by Wedbush indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price. However, the maintained Neutral rating suggests that the overall outlook for the company remains stable.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100